Jukka Kanerva
Overview
Explore the profile of Jukka Kanerva including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
46
Citations
624
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Schafer Hackenhaar F, Refhagen N, Hagleitner M, van Leeuwen F, Marquart H, Madsen H, et al.
Blood
. 2025 Jan;
PMID: 39841000
Current intensive treatment of pediatric T-cell acute lymphoblastic leukemia (T-ALL) has substantial side-effects, highlighting a need for novel biomarkers to improve risk stratification. Canonical biomarkers such as genetics and immunophenotype...
2.
Pihlajoki M, Eloranta K, Nousiainen R, Vayrynen V, Soini T, Kyronlahti A, et al.
Adv Biol Regul
. 2024 Nov;
:100997.
PMID: 39492287
Our research laboratory has a longstanding interest in developmental disorders and embryonic tumors, and recent efforts have focused on the pathogenesis of pediatric liver tumors. This review focuses on hepatoblastoma...
3.
Green D, Ewijk R, Tirtei E, Andreou D, Baecklund F, Baumhoer D, et al.
Clin Cancer Res
. 2024 Jun;
30(16):3395-3406.
PMID: 38869831
Osteosarcoma and Ewing sarcoma are bone tumors mostly diagnosed in children, adolescents, and young adults. Despite multimodal therapy, morbidity is high and survival rates remain low, especially in the metastatic...
4.
Rechl V, Ranft A, Bhadri V, Brichard B, Collaud S, Cyprova S, et al.
Sarcoma
. 2024 Mar;
2024:4751914.
PMID: 38524902
Background: Ewing sarcoma (EwS) is a rare and highly malignant bone tumor primarily affecting children, adolescents, and young adults. The pelvis, trunk, and lower extremities are the most common sites,...
5.
Viinikainen K, Isohanni P, Kanerva J, Lonnqvist T, Lauronen L
Clin Neurophysiol Pract
. 2024 Mar;
9:94-101.
PMID: 38440119
Objective: Vincristine, a widely used anticancer chemotherapy drug, may cause polyneuropathy (PNP), potentially resulting in permanent functional impairment. We characterized the occurrence and development of vincristine-induced neuropathy (VIPN) in early...
6.
Krali O, Marincevic-Zuniga Y, Arvidsson G, Enblad A, Lundmark A, Sayyab S, et al.
NPJ Precis Oncol
. 2023 Dec;
7(1):131.
PMID: 38066241
Genomic analyses have redefined the molecular subgrouping of pediatric acute lymphoblastic leukemia (ALL). Molecular subgroups guide risk-stratification and targeted therapies, but outcomes of recently identified subtypes are often unclear, owing...
7.
Koch R, Haveman L, Ladenstein R, Brichard B, Jurgens H, Cyprova S, et al.
Clin Cancer Res
. 2023 Oct;
29(24):5057-5068.
PMID: 37843857
Purpose: The phase III, open-label, prospective, multicenter, randomized Ewing 2008R1 trial (EudraCT2008-003658-13) was conducted in 12 countries to evaluate the effect of zoledronic acid (ZOL) maintenance therapy compared with no...
8.
Heesen P, Ranft A, Bhadri V, Brichard B, Collaud S, Cyprova S, et al.
Eur J Cancer
. 2023 Aug;
192:113260.
PMID: 37595489
Background: Local treatment is a crucial element in the standard of care for Ewing sarcoma (EWS). While systemic treatment is improved in randomised clinical trials, local treatment modalities are discussed...
9.
Kersting J, Ranft A, Bhadri V, Brichard B, Collaud S, Cyprova S, et al.
Adv Radiat Oncol
. 2023 Jun;
8(4):101269.
PMID: 37334316
Purpose: Radiation therapy (RT) is an integral part of Ewing sarcoma (EwS) therapy. The Ewing 2008 protocol recommended RT doses ranging from 45 to 54 Gy. However, some patients received...
10.
Koch R, Gelderblom H, Haveman L, Brichard B, Jurgens H, Cyprova S, et al.
J Clin Oncol
. 2022 Apr;
40(21):2307-2320.
PMID: 35427190
Purpose: Ewing 2008R3 was conducted in 12 countries and evaluated the effect of treosulfan and melphalan high-dose chemotherapy (TreoMel-HDT) followed by reinfusion of autologous hematopoietic stem cells on event-free survival...